Booth of Huons Group's Humedics, Huons Meditech, and Huons Biopharma participating in the aesthetic exhibition 'Dubai Derma'. Photo by Huons Group
Huons Group attended a skin beauty exhibition held in Dubai, Middle East, introducing each company's products and technologies to expand its global influence.
HuMedics Co., Ltd., Huons Meditech Co., Ltd., and Huons Biopharma Co., Ltd. announced on the 17th that they participated in 'Dubai Derma 2025,' the largest dermatology exhibition in the Middle East, held from the 14th to the 16th at the Dubai World Trade Center.
Dubai Derma is the 24th edition this year and is the largest dermatology specialized exhibition in the Middle East and North Africa (MENA) region. It is an event where companies and experts in medical devices, aesthetics, and cosmeceutical fields gather to communicate, hold seminars, and exchange ideas to develop the Middle Eastern skin beauty industry.
At this exhibition, HuMedics secured a foothold for expanding into the Middle Eastern market by signing supply contracts for its flagship hyaluronic acid (HA) filler 'Elravie' with Saudi Arabia, Lebanon, and Syria.
Elravie Premier is a filler made using HuMedics' technology that maintains the inherent viscosity of HA. It has previously received product approvals in South Korea, the European Union (CE), China’s National Medical Products Administration (NMPA), and Russia’s Federal Service for Surveillance in Healthcare (RZN). Currently, it is exported to 19 countries, including China and Brazil.
Kang Min-jong, CEO of HuMedics, said, "Elravie has already earned deep trust from Middle Eastern buyers based on its excellent efficacy and safety. We will actively expand the Middle Eastern market through entry into the important Saudi Arabian market."
Huons Meditech attracted attention from buyers at the exhibition by introducing 'Derma Shine Pro.' Derma Shine Pro is an input-sensing automatic injection device that injects high-molecular and high-content hyaluronic acid throughout the face. Huons Meditech surpassed cumulative sales of 20,000 units of the 'Derma Shine' product line at the end of last year.
Lee Jin-seok, CEO of Huons Meditech, said, "Through this exhibition, we plan to build new business opportunities in the Middle East and further expand our influence in the global market. We will strengthen our position in the global medical device market through active overseas marketing."
Huons Biopharma attracted interest by introducing its botulinum toxin products and technologies at the exhibition. Huons Biopharma has obtained product approvals for botulinum toxin in 15 overseas markets, including Russia, Southeast Asia (such as Thailand), and the Middle East (such as Iraq), and is currently undergoing product approval procedures in China.
A Huons Biopharma official stated, "Taking this opportunity of participating in Dubai Derma 2025, we will actively promote the competitiveness of our botulinum toxin products and secure partners to expand the Middle Eastern market."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
